在第二阶段试验中,在7天之内,所有38名病人的ProLectin-M已消除病毒,没有反弹。 ProLectin-M cleared virus in all 38 patients within 7 days, with no rebounds, in a Phase 2 trial.

Bioxytran Inc.报告其实验性口服治疗试验第二阶段试验结果为 " ProLectin-M " ,显示所有38名急性病毒感染的参与者在第7天完成病毒检查,14天的后续跟踪中没有反弹。 Bioxytran, Inc. reported positive Phase 2 trial results for its experimental oral treatment ProLectin-M, showing all 38 participants with acute viral infection achieved complete viral clearance by day 7, with no rebounds during a 14-day follow-up. 这种治疗堵塞了卡通蛋白,以防止病毒进入,结果迅速,一些病人早在第3天就清除了病毒。 The treatment, which blocks galectin proteins to prevent viral entry, demonstrated rapid results, with some patients clearing the virus as early as day 3. 调查结果支持每日四元剂量,推动药物发展,并计划进行监管讨论和探索更广泛的抗病毒应用。 The findings support a four-tablet daily dose and advance the drug’s development, with plans to pursue regulatory discussions and explore broader antiviral applications.